The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2009, 182, 6401 -6409
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0801481

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sundstrom, J. B.
Right arrow Articles by Kirshenbaum, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sundstrom, J. B.
Right arrow Articles by Kirshenbaum, A. S.

IgE-Fc{epsilon}RI Interactions Determine HIV Coreceptor Usage and Susceptibility to Infection during Ontogeny of Mast Cells1

J. Bruce Sundstrom2,*, Gregory A. Hair*, Aftab A. Ansari*, W. Evan Secor{dagger}, Alasdair M. Gilfillan{ddagger}, Dean D. Metcalfe{ddagger} and Arnold S. Kirshenbaum{ddagger}

* Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322; {dagger} Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341; and {ddagger} Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Progenitor mast cells (prMCs), derived from CD34+ precursors are CD4+/CCR5+/CXCR4+ and susceptible to CCR5(R5)-tropic virus but only marginally susceptible to CXCR4(X4)-tropic HIV. As infected prMCs mature within extravascular compartments, they become both latently infected and HIV-infection resistant, and thus capable of establishing an inducible reservoir of CCR5-tropic infectious clones. In this report we provide the first evidence that IgE-Fc{epsilon}RI interactions, occurring during a unique period of mast cell (MC) ontogeny, enhance prMC susceptibility to X4 and R5X4 virus. IgE-Fc{epsilon}RI interactions significantly increased expression of CXCR4 mRNA (~400- to 1800-fold), enhanced prMC susceptibility to X4 and R5X4 virus (~3000- to 16,000-fold), but had no significant effect on CD4, CCR3, or CCR5 expression, susceptibility to R5 virus, or degranulation. Enhanced susceptibility to infection with X4 virus occurred during the first 3–5 wk of MC ontogeny and was completely inhibited by CXCR4-specific peptide antagonists and omalizumab, a drug that inhibits IgE-Fc{epsilon}RI interactions. IgE-Fc{epsilon}RI coaggregation mediated by HIVgp120 or Schistosoma mansoni soluble egg Ag accelerated maximal CXCR4 expression and susceptibility to X4 virus by prMCs. Our findings suggest that for HIV-positive individuals with atopic or helminthic diseases, elevated IgE levels could potentially influence the composition of CXCR4-tropic and R5X4-tropic variants archived within the long-lived tissue MC reservoir created during infection.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by Grant R01AI062383 from the National Institutes of Health (to J.B.S.), in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health, and in part by base Grant RR-00165 from the Animal Resources Program of the National Institutes of Health awarded to the Yerkes National Primate Research Center at Emory University.

2 Address correspondence and reprint requests to Dr. J. Bruce Sundstrom, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-7616. E-mail address: sundstromj{at}niaid.nih.gov

3 Abbreviations used in this paper: prMC, progenitor mast cell; MC, mast cell; SS, strong stop; β-hex, β-hexosaminidase; SmEA, Schistosoma mansoni egg Ag; DC, dendritic cell; HAART, highly active antiretroviral therapy.


Related articles in The JI:

IN THIS ISSUE

The JI 2009 182: 5887-5888. [Full Text]  






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.